Seven Fleet Capital Management LP Increases Position in Abivax SA Sponsored ADR $ABVX

Seven Fleet Capital Management LP raised its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report) by 158.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,334 shares of the company’s stock after purchasing an additional 68,282 shares during the period. Abivax comprises 2.5% of Seven Fleet Capital Management LP’s portfolio, making the stock its 7th biggest position. Seven Fleet Capital Management LP’s holdings in Abivax were worth $14,836,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in ABVX. Nan Fung Trinity HK Ltd. raised its holdings in shares of Abivax by 11.8% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares in the last quarter. Total Clarity Wealth Management Inc. bought a new position in shares of Abivax during the fourth quarter valued at approximately $1,247,000. Brummer Multi Strategy AB purchased a new position in Abivax during the fourth quarter valued at approximately $1,939,000. Militia Capital Management LLC purchased a new position in Abivax during the first quarter valued at approximately $1,893,000. Finally, Jennison Associates LLC purchased a new position in Abivax during the fourth quarter valued at approximately $17,249,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Get Abivax alerts:

Abivax Stock Down 1.2%

Shares of NASDAQ:ABVX opened at $116.52 on Thursday. Abivax SA Sponsored ADR has a 52-week low of $69.81 and a 52-week high of $148.83. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of -22.36 and a beta of 1.03. The business has a 50-day moving average price of $123.85 and a 200-day moving average price of $119.06.

Analyst Ratings Changes

A number of research firms have weighed in on ABVX. Guggenheim restated a “buy” rating on shares of Abivax in a report on Tuesday, June 30th. Citigroup restated an “outperform” rating on shares of Abivax in a research note on Tuesday, June 2nd. Jefferies Financial Group raised Abivax from a “hold” rating to a “buy” rating and raised their price objective for the company from $108.00 to $158.00 in a research report on Tuesday, June 30th. Wolfe Research set a $136.00 target price on shares of Abivax in a report on Wednesday, June 3rd. Finally, Truist Financial increased their price target on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Abivax has a consensus rating of “Moderate Buy” and an average price target of $156.50.

Get Our Latest Stock Report on ABVX

Abivax Company Profile

(Free Report)

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

Featured Articles

• Five stocks we like better than Abivax
• Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
• Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
• Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
• Can Tesla’s Flying Roadster Distract From Its Real Risks?

Want to see what other hedge funds are holding ABVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX – Free Report).

Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.